Latest & greatest articles for azithromycin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on azithromycin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on azithromycin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for azithromycin

21. Adjunct Use of Systemic Azithromycin with Scaling and Root Planing in Treatment of Chronic Periodontitis Results in Only Limited Gain in Clinical Attachment Level and Limited Probing Depth Reduction

Adjunct Use of Systemic Azithromycin with Scaling and Root Planing in Treatment of Chronic Periodontitis Results in Only Limited Gain in Clinical Attachment Level and Limited Probing Depth Reduction UTCAT3102, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Adjunct Use of Systemic Azithromycin with Scaling and Root Planing in Treatment of Chronic Periodontitis Results in Only Limited Gain in Clinical Attachment Level (...) and Limited Probing Depth Reduction Clinical Question In a patient with chronic periodontitis, how does adjunct systemic azithromycin in conjunction with scaling and root planing versus scaling and root planing alone compare in terms of periodontal outcomes including probing depths and clinical attachment levels? Clinical Bottom Line Systemic use of azithromycin in chronic periodontitis patients has only limited benefits in terms of clinical attachment level gains and probing depth reduction based

2016 UTHSCSA Dental School CAT Library

22. A randomised, double-blind, placebo-controlled study to evaluate the efficacy of oral azithromycin as a supplement to standard care for adult patients with acute exacerbations of asthma (the AZALEA trial) Full Text available with Trip Pro

A randomised, double-blind, placebo-controlled study to evaluate the efficacy of oral azithromycin as a supplement to standard care for adult patients with acute exacerbations of asthma (the AZALEA trial) A randomised, double-blind, placebo-controlled study to evaluate the efficacy of oral azithromycin as a supplement to standard care for adult patients with acute exacerbations of asthma (the AZALEA trial) Journals Library An error occurred retrieving content to display, please try again (...) . >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} In adults with acute exacerbations of asthma, giving azithromycin in addition to standard care produced no statistically significant or clinically important benefit {{author}} {{($index

2016 NIHR HTA programme

23. Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. Full Text available with Trip Pro

Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. The addition of azithromycin to standard regimens for antibiotic prophylaxis before cesarean delivery may further reduce the rate of postoperative infection. We evaluated the benefits and safety of azithromycin-based extended-spectrum prophylaxis in women undergoing nonelective cesarean section.In this trial conducted at 14 centers in the United States, we studied 2013 women who had a singleton pregnancy with a gestation of 24 weeks (...) or more and who were undergoing cesarean delivery during labor or after membrane rupture. We randomly assigned 1019 to receive 500 mg of intravenous azithromycin and 994 to receive placebo. All the women were also scheduled to receive standard antibiotic prophylaxis. The primary outcome was a composite of endometritis, wound infection, or other infection occurring within 6 weeks.The primary outcome occurred in 62 women (6.1%) who received azithromycin and in 119 (12.0%) who received placebo (relative

2016 NEJM Controlled trial quality: predicted high

24. Azithromycin versus Doxycycline for Chlamydia. (Abstract)

Azithromycin versus Doxycycline for Chlamydia. 27144856 2016 05 05 2018 12 02 1533-4406 374 18 2016 05 05 The New England journal of medicine N. Engl. J. Med. Azithromycin versus Doxycycline for Chlamydia. 1787 10.1056/NEJMc1600830 Geisler William M WM Perry Raymond C W RC Kerndt Peter R PR eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anti-Bacterial Agents 83905-01-5 Azithromycin N12000U13O Doxycycline AIM IM N Engl J Med. 2015 Dec 24;373(26):2512-21 26699167 N Engl J Med (...) . 2016 May 5;374(18):1786 27144857 N Engl J Med. 2016 May 5;374(18):1786-7 27144858 Anti-Bacterial Agents therapeutic use Azithromycin therapeutic use Chlamydia Infections drug therapy Chlamydia trachomatis Doxycycline therapeutic use Female Humans Male 2016 5 5 6 0 2016 5 6 6 0 2016 5 6 6 1 ppublish 27144856 10.1056/NEJMc1600830 10.1056/NEJMc1600830#SA3

2016 NEJM

25. Azithromycin versus Doxycycline for Chlamydia. Full Text available with Trip Pro

Azithromycin versus Doxycycline for Chlamydia. 27144857 2016 05 05 2018 12 02 1533-4406 374 18 2016 05 05 The New England journal of medicine N. Engl. J. Med. Azithromycin versus Doxycycline for Chlamydia. 1786 10.1056/NEJMc1600830 Schachter Julius J University of California, San Francisco, San Francisco, CA julius.schachter@ucsf.edu. eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anti-Bacterial Agents 83905-01-5 Azithromycin N12000U13O Doxycycline AIM IM N Engl J Med. 2015 (...) Dec 24;373(26):2512-21 26699167 N Engl J Med. 2016 May 5;374(18):1787 27144856 Anti-Bacterial Agents therapeutic use Azithromycin therapeutic use Chlamydia Infections drug therapy Chlamydia trachomatis Doxycycline therapeutic use Female Humans Male 2016 5 5 6 0 2016 5 6 6 0 2016 5 6 6 1 ppublish 27144857 10.1056/NEJMc1600830 10.1056/NEJMc1600830#SA1

2016 NEJM

26. Azithromycin versus Doxycycline for Chlamydia. Full Text available with Trip Pro

Azithromycin versus Doxycycline for Chlamydia. 27144858 2016 05 05 2018 12 02 1533-4406 374 18 2016 05 05 The New England journal of medicine N. Engl. J. Med. Azithromycin versus Doxycycline for Chlamydia. 1786-7 10.1056/NEJMc1600830 Kreuter Alexander A Helios St. Elisabeth Hospital, Oberhausen, Germany alexander.kreuter@helios-kliniken.de. Wieland Ulrike U University of Cologne, Cologne, Germany. eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anti-Bacterial Agents 83905-01-5 (...) Azithromycin N12000U13O Doxycycline AIM IM N Engl J Med. 2015 Dec 24;373(26):2512-21 26699167 N Engl J Med. 2016 May 5;374(18):1787 27144856 Anti-Bacterial Agents therapeutic use Azithromycin therapeutic use Chlamydia Infections drug therapy Chlamydia trachomatis Doxycycline therapeutic use Female Humans Male 2016 5 5 6 0 2016 5 6 6 0 2016 5 6 6 1 ppublish 27144858 10.1056/NEJMc1600830 10.1056/NEJMc1600830#SA2

2016 NEJM

27. Incidence of Sustained Ventricular Tachycardia in Patients with Prolonged QTc After the Administration of Azithromycin: A Retrospective Study Full Text available with Trip Pro

Incidence of Sustained Ventricular Tachycardia in Patients with Prolonged QTc After the Administration of Azithromycin: A Retrospective Study Azithromycin has been associated with abnormalities of cardiac repolarization and development of torsades de pointes. Observational data suggest that the risk of death from cardiovascular causes is increased in patients taking azithromycin. Little is known regarding the risk of ventricular arrhythmia in patients with prolongation of the corrected QT (...) interval who receive azithromycin.The purpose of this study was to determine the incidence of sustained ventricular tachycardia in patients with prolonged corrected QT (QTc) who subsequently received azithromycin.We performed a retrospective cohort analysis of the incidence of sustained ventricular tachycardia in patients with prolonged QTc (greater than 450 ms) who successively received intravenous (IV) and/or oral azithromycin. Patients hospitalized in a tertiary care teaching hospital between

2016 Drugs - real world outcomes

28. Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial. Full Text available with Trip Pro

Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial. Many preschool children develop recurrent, severe episodes of lower respiratory tract illness (LRTI). Although viral infections are often present, bacteria may also contribute to illness pathogenesis. Strategies that effectively attenuate such episodes are needed.To evaluate if early administration of azithromycin (...) LRTIs and minimal day-to-day impairment.Participants were randomly assigned to receive azithromycin (12 mg/kg/d for 5 days; n = 307) or matching placebo (n = 300), started early during each predefined RTI (child's signs or symptoms prior to development of LRTI), based on individualized action plans, over a 12- through 18-month period.The primary outcome measure was the number of RTIs not progressing to a severe LRTI, measured at the level of the RTI, that would in clinical practice trigger

2015 JAMA Controlled trial quality: predicted high

29. Azithromycin in early infancy and pyloric stenosis Full Text available with Trip Pro

Azithromycin in early infancy and pyloric stenosis Use of oral erythromycin in infants is associated with infantile hypertrophic pyloric stenosis (IHPS). The risk with azithromycin remains unknown. We evaluated the association between exposure to oral azithromycin and erythromycin and subsequent development of IHPS.A retrospective cohort study of children born between 2001 and 2012 was performed utilizing the military health system database. Infants prescribed either oral erythromycin (...) or azithromycin as outpatients in the first 90 days of life were evaluated for development of IHPS. Specific diagnostic and procedural codes were used to identify cases of IHPS.A total of 2466 of 1 074 236 children in the study period developed IHPS. Azithromycin exposure in the first 14 days of life demonstrated an increased risk of IHPS (adjusted odds ratio [aOR], 8.26; 95% confidence interval [CI], 2.62-26.0); exposure between 15 and 42 days had an aOR of 2.98 (95% CI, 1.24-7.20). An association between

2015 EvidenceUpdates

30. Azithromycin (Zedbac®)

Azithromycin (Zedbac®) Azithromycin (Zedbac®) Azithromycin (Zedbac®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Azithromycin (Zedbac®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG (...) Secretariat Assessment Report Advice No. 1914. 2014 Authors' conclusions Azithromycin (Zedbac®) 500 mg powder for solution for infusion is recommended as an option for restricted use within NHS Wales. Azithromycin (Zedbac®) 500 mg powder for solution for infusion should be restricted for use within NHS Wales for the treatment of community-acquired pneumonia (CAP) due to susceptible microorganisms, in adult patients where initial intravenous therapy is required. Azithromycin (Zedbac®) 500 mg powder

2015 Health Technology Assessment (HTA) Database.

31. Azithromycin (Zedbac) - for the treatment of community-acquired pneumonia (CAP)

Azithromycin (Zedbac) - for the treatment of community-acquired pneumonia (CAP) Final Appraisal Recommendation Advice No: 1914 – July 2014 Azithromycin (Zedbac ® ) 500 mg powder for solution for infusion Limited submission by Aspire Pharma Ltd Additional notes: ? The company submission included evidence for azithromycin (Zedbac ® ) in the treatment of CAP due to susceptible microorganisms, in adult patients where initial intravenous therapy is required. No evidence was provided for azithromycin (...) /patient carers (where available) and the lay member perspective. This recommendation has been ratified by Welsh Government and will be considered for review every three years. Recommendation of AWMSG Azithromycin (Zedbac ® ) 500 mg powder for solution for infusion is recommended as an option for restricted use within NHS Wales. Azithromycin (Zedbac ® ) 500 mg powder for solution for infusion should be restricted for use within NHS Wales for the treatment of community- acquired pneumonia (CAP) due

2014 All Wales Medicines Strategy Group

32. Azithromycin

Azithromycin USE OF AZITHROMYCIN IN PREGNANCY 0344 892 0909 USE OF AZITHROMYCIN IN PREGNANCY (Date of issue: June 2017 , Version: 2.1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary The macrolide antibiotics include azithromycin, clarithromycin (...) , erythromycin, spiramycin and telithromycin. Macrolides have an antibacterial spectrum similar to that of penicillin and are thus considered an alternative in penicillin-allergic patients. Indications include sinusitis, otitis media, pharyngitis, tonsillitis, bronchitis, skin and soft tissue infection. Azithromycin is also used in the treatment of chlamydia, and clarithromycin in the eradication of Helicobacter pylori . The considerable data for macrolides as a class, and for erythromycin specifically, do

2014 UK Teratology Information Service

33. Cystic fibrosis: long-term azithromycin

Cystic fibrosis: long-term azithromycin Cystic fibrosis: long-term azithrom Cystic fibrosis: long-term azithromy ycin cin Evidence summary Published: 25 November 2014 nice.org.uk/guidance/esuom37 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in November 2014. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date information (...) . Summary A Cochrane review (10 studies, n=959) assessed the use of long-term azithromycin for cystic fibrosis. Six studies (n=836) had a low risk of bias. Various dosing regimens were used, the most common being 250-500 mg 3 times weekly. In 4 studies (n=549), treatment with azithromycin statistically significantly improved forced expired volume in 1 second (FEV 1 ; the primary outcome) over 6 months compared with placebo. Azithromycin doubled the rate of being free of exacerbations over 6 months

2014 National Institute for Health and Clinical Excellence - Advice

34. Non-cystic fibrosis bronchiectasis: long-term azithromycin

Non-cystic fibrosis bronchiectasis: long-term azithromycin Non-cystic fibrosis bronchiectasis: long-term Non-cystic fibrosis bronchiectasis: long-term azithrom azithromy ycin cin Evidence summary Published: 25 November 2014 nice.org.uk/guidance/esuom38 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in November 2014. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE (...) websites for up-to-date information. Summary Two randomised controlled trials (BAT: Altenburg J et al. 2013; n=89 and EMBRACE: Wong C et al. 2012; n=141) found that, compared with placebo, azithromycin reduced the rate of pulmonary exacerbations needing antibiotics in adults with non-cystic fibrosis bronchiectasis over 6 to 12 months. However, the evidence for other outcomes is unclear and the improvement in exacerbations must be balanced against the risk of experiencing adverse events

2014 National Institute for Health and Clinical Excellence - Advice

35. Cohort study: Azithromycin associated with a reduction in 90-day mortality among older pneumonia patients, although a true clinical benefit is uncertain Full Text available with Trip Pro

Cohort study: Azithromycin associated with a reduction in 90-day mortality among older pneumonia patients, although a true clinical benefit is uncertain Azithromycin associated with a reduction in 90-day mortality among older pneumonia patients, although a true clinical benefit is uncertain | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how (...) we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Azithromycin associated with a reduction in 90-day mortality among older pneumonia patients

2014 Evidence-Based Medicine

36. Azithromycin use in paediatrics: A practical overview

Azithromycin use in paediatrics: A practical overview Azithromycin is an antibiotic that is commonly prescribed for upper  and lower respiratory tract infections in children. While it has proven benefits, some concerns regarding azithromycin use have arisen in recent years. This practice point considers azithromycin therapy for acute respiratory infections in otherwise healthy children. Pharmacokinetics, spectrum of activity, the problem of resistant bacteria and clinical aspects (...) are considered, along with recommendations for use and contraindications. Azithromycin should be avoided in patients with a significant risk of bacteremia. It is associated with pneumococcal resistance and, with stated exceptions, is generally not recommended for the treatment of acute pharyngitis, acute otitis media or pneumococcal community-acquired pneumonia in the paediatric population. Key Words: Antibiotics; Azithromycin; Infections; Macrolides; Resistance; Treatment  

2013 Canadian Paediatric Society

37. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. Full Text available with Trip Pro

Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. Macrolide antibiotics have been shown beneficial in cystic fibrosis (CF) and diffuse panbronchiolitis, and earlier findings also suggest a benefit in non-CF bronchiectasis.To determine the efficacy of macrolide maintenance treatment for adults with non-CF bronchiectasis.The BAT (Bronchiectasis and Long-term Azithromycin Treatment (...) , and quality of life.Forty-three participants (52%) received azithromycin and 40 (48%) received placebo and were included in the modified intention-to-treat analysis. At end of study, the median number of exacerbations in the azithromycin group was 0 (interquartile range [IQR], 0-1), compared with 2 (IQR, 1-3) in the placebo group (P < .001). Thirty-two (80%) placebo-treated vs 20 (46%) azithromycin-treated individuals had at least 1 exacerbation (hazard ratio, 0.29 [95% CI, 0.16-0.51]). In a mixed-model

2013 JAMA Controlled trial quality: predicted high

38. Azithromycin Therapy in Hospitalized Infants with Acute Bronchiolitis is Not Associated with Better Clinical Outcomes: A Randomized, Double-Blinded, and Placebo-Controlled Clinical Trial (Abstract)

Azithromycin Therapy in Hospitalized Infants with Acute Bronchiolitis is Not Associated with Better Clinical Outcomes: A Randomized, Double-Blinded, and Placebo-Controlled Clinical Trial To test the hypothesis that azithromycin reduces the length of hospitalization and oxygen requirement in infants with acute viral bronchiolitis (AB).We performed a randomized, double-blinded, placebo-controlled trial in southern Brazil, from 2009 to 2011. Infants (<12 months of age) hospitalized with AB were (...) recruited in 2 hospitals. Patients were randomized to receive either azithromycin or placebo, administered orally, for 7 days. At enrollment, clinical data were recorded and nasopharyngeal samples were collected for viral identification through immunofluorescence. Main outcomes were duration of oxygen requirement and length of hospitalization.One hundred eighty-four patients were included in the study (azithromycin 88 subjects, placebo 96 subjects). Baseline clinical characteristics and viral

2012 EvidenceUpdates Controlled trial quality: predicted high

39. Azithromycin and the risk of cardiovascular death. Full Text available with Trip Pro

Azithromycin and the risk of cardiovascular death. Although several macrolide antibiotics are proarrhythmic and associated with an increased risk of sudden cardiac death, azithromycin is thought to have minimal cardiotoxicity. However, published reports of arrhythmias suggest that azithromycin may increase the risk of cardiovascular death.We studied a Tennessee Medicaid cohort designed to detect an increased risk of death related to short-term cardiac effects of medication, excluding patients (...) with serious noncardiovascular illness and person-time during and shortly after hospitalization. The cohort included patients who took azithromycin (347,795 prescriptions), propensity-score-matched persons who took no antibiotics (1,391,180 control periods), and patients who took amoxicillin (1,348,672 prescriptions), ciprofloxacin (264,626 prescriptions), or levofloxacin (193,906 prescriptions).During 5 days of therapy, patients taking azithromycin, as compared with those who took no antibiotics, had

2012 NEJM

40. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. (Abstract)

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Azithromycin is a macrolide antibiotic with anti-inflammatory and immunomodulatory properties. We tested the hypothesis that azithromycin would decrease the frequency of exacerbations, increase lung function, and improve health-related quality of life in patients with non-cystic fibrosis bronchiectasis.We undertook a randomised, double-blind (...) , placebo-controlled trial at three centres in New Zealand. Between Feb 12, 2008, and Oct 15, 2009, we enrolled patients who were 18 years or older, had had at least one pulmonary exacerbation requiring antibiotic treatment in the past year, and had a diagnosis of bronchiectasis defined by high-resolution CT scan. We randomly assigned patients to receive 500 mg azithromycin or placebo three times a week for 6 months in a 1:1 ratio, with a permuted block size of six and sequential assignment stratified

2012 Lancet Controlled trial quality: predicted high